Drug Trial Radar · NCT02791334
A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors
Last checked: Nov 19, 2026Latest source record: Sep 27, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
164
Actual
Start
Jun 29, 2016
Primary completion
May 22, 2020
Study completion Jun 27, 2024
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- Jun 6, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study is to evaluate the safety and tolerability of anti-programmed cell death ligand 1 (PD-L1) checkpoint antibody LY3300054 in participants with advanced refractory solid tumors.
Conditions
- Solid Tumor
- Microsatellite Instability-High (MSI-H) Solid Tumors
- Cutaneous Melanoma
- Pancreatic Cancer
- Breast Cancer (HR+HER2-)
Interventions
LY3300054Drug
Administered IV
RamucirumabDrug
Administered IV
AbemaciclibDrug
Administered orally
MerestinibDrug
Administered orally
LY3321367Drug
Administered IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with LY3300054 Dose Limiting Toxicities (DLTs)Time frame: Baseline through Cycle 1 (Approximately 28 Days)
Locations
14 sites in 7 countries. Site status is shown where the registry gives one.
Tennessee Oncology PLLC
Nashville, Tennessee
University of Texas MD Anderson Cancer Center
Houston, Texas
The START Center for Cancer Care
San Antonio, Texas
Cliniques Universitaires Saint-Luc
Brussels, Belgium
Universitair Ziekenhuis Antwerpen
Edegem, Belgium
Princess Margaret Hospital
Toronto, Ontario, Canada
Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest
Bordeaux, France
Gustave Roussy
Villejuif, France
Seoul National University Hospital
Seoul, South Korea
Severance Hospital Yonsei University Health System
Seoul, South Korea
Hospital Universitario Fundación Jiménez Díaz
Madrid, Spain
Hospital Madrid Norte Sanchinarro
Madrid, Spain
National Cheng Kung University Hospital
Tainan, Taiwan
National Taiwan University Hospital
Taipei, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.